Japan has approved ground-breaking stem-cell treatments for Parkinson's and severe heart failure, one of the manufacturers and media reports, with the therapies expected to reach patients within months. The breakthrough offers new hope for millions of people living with the neurological disorder across the world and could mark the beginning of a new era in regenerative medicine.
Pharmaceutical company Sumitomo Pharma said it received the green light for the manufacture and sale of Amchepry, its Parkinson's disease treatment that transplants stem cells into a patient's brain. According to media reports, Japan's health ministry also gave the go-ahead to ReHeart, heart muscle sheets developed by medical startup Cuorips that can help form new blood vessels and restore heart function.
Parkinson’s disease is a chronic and progressive neurological condition that affects movement, balance, and coordination. It occurs when dopamine-producing neurons in the brain gradually die, leading to symptoms such as tremors, stiffness, slowed movement, and difficulty with balance. Global health estimates say more than 10 million people worldwide live with Parkinson’s disease, and current treatments mainly focus on managing symptoms rather than repairing the underlying brain damage.
The health ministry says the treatments could be on the market and rolled out to patients as early as this summer, becoming the world's first commercially available medical products using (iPS) cells.
Also read:Your Eyes May Be Damaged Even With 6/6 Vision, Experts Warn
Induced pluripotent stem cells (iPS cells) are a revolutionary technology that allows scientists to reprogram adult cells into stem cells capable of becoming different types of cells in the body.
Researchers convert these stem cells into dopamine-producing neurons and transplant them into the patient’s brain. The goal is to replace the damaged nerve cells responsible for Parkinson’s symptoms, potentially restoring normal dopamine levels and improving motor function.
The treatment was developed by scientists at Kyoto University and affiliated medical institutions, which have been at the forefront of stem cell research for more than a decade. Clinical trials conducted in Japan showed encouraging results, with patients experiencing improved motor control and no major safety concerns during the study period.
Japanese scientist Shinya Yamanaka won the Nobel Prize in 2012 for his research into iPS, which has the potential to develop into any cell in the body. “I hope this will bring relief to patients not only in Japan but around the world,” health minister Kenichiro Ueno said in a press conference. “We will promptly carry out all necessary procedures to ensure it reaches all patients without fail.”
The approval is significant because it represents the first time a stem cell–based therapy for Parkinson’s disease has received regulatory clearance anywhere in the world. Until now, Parkinson’s treatments have relied on medications such as levodopa or surgical options like deep brain stimulation, which help control symptoms but do not halt or reverse disease progression.
Source: India Latest News, Breaking News Today, Top News Headlines | Times Now
